Michele Hilmer

Michele brings over thirty years of diverse pharmaceutical and device clinical trial expertise to SIA and oversees both ongoing global post-market studies and a first-in-class U.S.-based Investigational Device Exemption (IDE) study of breast reconstruction. Her previous work includes positions with the DOD, research sites, CROs, and sponsor companies. She is spearheading the planning and development of upcoming clinical trials and will oversee operations to ensure trial conduct adheres to GCP guidelines and FDA regulations.